ZA200604971B - 3-Cyano-quinoline derivatives with antiproliferative activity - Google Patents

3-Cyano-quinoline derivatives with antiproliferative activity

Info

Publication number
ZA200604971B
ZA200604971B ZA200604971A ZA200604971A ZA200604971B ZA 200604971 B ZA200604971 B ZA 200604971B ZA 200604971 A ZA200604971 A ZA 200604971A ZA 200604971 A ZA200604971 A ZA 200604971A ZA 200604971 B ZA200604971 B ZA 200604971B
Authority
ZA
South Africa
Prior art keywords
cyano
antiproliferative activity
quinoline derivatives
quinoline
derivatives
Prior art date
Application number
ZA200604971A
Other languages
English (en)
Inventor
Freyne Eddy Jean Edgard
Van Emelen Kristof
Timothy Pietro Suren Perera
Peter Jacobus Johannes Antonius Buijnsters
Werner Constan Johan Embrechts
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34684508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200604971(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ZA200604971B publication Critical patent/ZA200604971B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4748Quinolines; Isoquinolines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA200604971A 2003-12-18 2006-06-15 3-Cyano-quinoline derivatives with antiproliferative activity ZA200604971B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EPPCT/EP03/51059 2003-12-18

Publications (1)

Publication Number Publication Date
ZA200604971B true ZA200604971B (en) 2009-05-27

Family

ID=34684508

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200604971A ZA200604971B (en) 2003-12-18 2006-06-15 3-Cyano-quinoline derivatives with antiproliferative activity

Country Status (23)

Country Link
US (4) US7655642B2 (es)
EP (1) EP1696914B1 (es)
JP (1) JP4892353B2 (es)
KR (1) KR101158440B1 (es)
CN (1) CN1893944B (es)
AR (1) AR047060A1 (es)
AT (1) ATE446750T1 (es)
AU (1) AU2004298784B2 (es)
BR (1) BRPI0417609B8 (es)
CA (1) CA2549728C (es)
DE (1) DE602004023876D1 (es)
EA (1) EA200601176A1 (es)
ES (1) ES2335216T3 (es)
HK (1) HK1095742A1 (es)
IL (1) IL176358A (es)
MX (1) MXPA06007018A (es)
NO (1) NO337622B1 (es)
NZ (1) NZ547795A (es)
SG (1) SG151288A1 (es)
TW (2) TWI374879B (es)
UA (1) UA83880C2 (es)
WO (1) WO2005058318A1 (es)
ZA (1) ZA200604971B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4892353B2 (ja) 2003-12-18 2012-03-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗増殖活性を有する3−シアノ−キノリン誘導体
JP4936897B2 (ja) 2003-12-18 2012-05-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗増殖剤としてのピリド−およびピリミドピリミジン誘導体
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
MY169441A (en) 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
KR101499594B1 (ko) 2005-11-16 2015-03-09 씨티아이 바이오파마 코포레이션 산소가 결합된 피리미딘 유도체
US10517876B2 (en) 2005-11-16 2019-12-31 Cti Biopharma Corp. Oxygen linked pyrimidine derivatives
CA2654583C (en) 2006-07-13 2015-11-24 Janssen Pharmaceutica N.V. Mtki quinazoline derivatives
WO2008087736A1 (ja) * 2007-01-19 2008-07-24 Ube Industries, Ltd. アラルキルオキシ又はヘテロアラルキルオキシ基を有する芳香族アミンの製法
AU2008265104B2 (en) * 2007-06-21 2013-09-12 Janssen Pharmaceutica Nv Indolin-2-ones and aza-indolin-2-ones
CA2693715C (en) 2007-07-27 2015-10-27 Janssen Pharmaceutica Nv Pyrrolopyrimidines
CN102127087B (zh) * 2011-01-21 2012-07-04 江苏先声药物研究有限公司 喹唑啉衍生物
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
BR112018006873A2 (pt) 2015-10-05 2018-11-06 The Trustees Of Columbia University In The City Of New York ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028613A (en) 1990-02-16 1991-07-02 Repligen Corporation Novel pyrroloquinoline alkaloids and methods of use
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
UA72749C2 (en) 1998-09-29 2005-04-15 White Holdings Corp Substituted 3-cyanoquinolines, a method for the preparation thereof (variants), pharmaceutical composition based thereon, a method for the treatment, inhibiting the growth or elimination of neoplasms and a method for the treatment, inhibiting progressing or elimination of polycystic kidney disease using them
IL164167A0 (en) * 2002-03-30 2005-12-18 Boehringer Ingelheim Pharma 4-(N-phenylamino)-quinazolines/ quinolines as tyrosine kinase inhibitors
JO2785B1 (en) * 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
JP4892353B2 (ja) 2003-12-18 2012-03-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗増殖活性を有する3−シアノ−キノリン誘導体

Also Published As

Publication number Publication date
JP4892353B2 (ja) 2012-03-07
MXPA06007018A (es) 2006-08-31
EA200601176A1 (ru) 2006-10-27
JP2007514711A (ja) 2007-06-07
ATE446750T1 (de) 2009-11-15
WO2005058318A1 (en) 2005-06-30
US20140256948A1 (en) 2014-09-11
CA2549728A1 (en) 2005-06-30
US20100069424A1 (en) 2010-03-18
US9365517B2 (en) 2016-06-14
DE602004023876D1 (de) 2009-12-10
CA2549728C (en) 2015-07-21
US20080139601A1 (en) 2008-06-12
TWI374879B (en) 2012-10-21
TWI389890B (zh) 2013-03-21
AU2004298784A1 (en) 2005-06-30
BRPI0417609B1 (pt) 2019-02-19
AR047060A1 (es) 2006-01-04
BRPI0417609A (pt) 2007-04-10
NZ547795A (en) 2009-07-31
SG151288A1 (en) 2009-04-30
KR101158440B1 (ko) 2012-07-06
ES2335216T3 (es) 2010-03-23
US8778920B2 (en) 2014-07-15
KR20070005560A (ko) 2007-01-10
AU2004298784B2 (en) 2011-06-09
EP1696914A1 (en) 2006-09-06
EP1696914B1 (en) 2009-10-28
US9040511B2 (en) 2015-05-26
CN1893944A (zh) 2007-01-10
US20130197022A1 (en) 2013-08-01
UA83880C2 (en) 2008-08-26
BRPI0417609B8 (pt) 2021-05-25
TW200530187A (en) 2005-09-16
NO337622B1 (no) 2016-05-09
IL176358A0 (en) 2006-10-05
NO20063324L (no) 2006-07-18
CN1893944B (zh) 2011-07-06
IL176358A (en) 2010-06-16
US7655642B2 (en) 2010-02-02
HK1095742A1 (en) 2007-05-18
TW201132628A (en) 2011-10-01

Similar Documents

Publication Publication Date Title
HK1095742A1 (en) 3-cyano-quinoline derivatives with antiproliferative activity
SI1583763T1 (sl) Benzoazolilpiperazinski derivati, ki imajo VR1 antagonistično delovanje
IL174533A0 (en) Quinazoline derivatives as antiproliferative agents
AP1850A (en) Spiroindolineplperidine derivatives
EG24050A (en) Heterocylocarboxamide derivatives
HK1077068A1 (en) Azolidinone-vinyl fused-benzene derivatives
EP1522540A4 (en) AZAARENE DERIVATIVES
PL375588A1 (en) Pyrimido compounds having antiproliferative activity
PL376475A1 (en) N-substituted-2-oxodihydropyridine derivatives
GB0317665D0 (en) Qinazoline derivatives
ZA200500471B (en) N-biarylmethyl aminocycloalkanecarboxamide derivatives
HK1086842A1 (en) Macrolide-conjugates with anti-inflammatory activity
AU2003222659A8 (en) 23-o-substituted 5-o-mycaminosyltylonide derivatives
DE60326941D1 (en) Rs
HK1099649A1 (en) Pesticidal 5-substituted-oxyalkylamino-1-arylpyrazole derivatives 5--
EP1531854A4 (en) O-DERIVATED NOCATHIACIN DERIVATIVES
GB0319793D0 (en) Pyridinylmorpholine derivatives
GB0213488D0 (en) 2-Naphthamide derivatives
MY144310A (en) 3-cyano-quinoline deriatives with antiproliferative activity
AU2003243397A8 (en) Homo-camptothecin derivatives
AU2003225764A8 (en) Aza-thioxanthenones with antitumor activity
AU2003224677A8 (en) Aza-benzothiopyranoindazoles with antitumor activity
GB0207572D0 (en) Easy fit cill
AU2003285777A8 (en) 3-substituted-4-pyrimidone derivatives
GB0210512D0 (en) Tetrahydro-napthalene derivatives